Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LRP Double Nickase Plasmid (h): sc-401589-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LRP Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LRP Double Nickase Plasmid (h) and LRP Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MVP. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LRP Antibody (1014): sc-23916
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LRP Double Nickase Plasmid (h) | sc-401589-NIC | 20 µg | $410.00 | |||
LRP Double Nickase Plasmid (h2) | sc-401589-NIC-2 | 20 µg | $410.00 |
Major vault protein (MVP), also known as lung resistance-related protein (LRP), is the principal structural component of vault ribonucleoprotein particles that participate in nucleocytoplasmic transport, signal integration, and cellular stress responses. MVP has been linked to modulation of PI3K/AKT, MAPK, and NF-κB-associated signaling and can influence endocytosis, autophagy, and innate immune signaling through interactions with multiple adaptor proteins. By affecting intracellular trafficking and the handling of xenobiotics, MVP is frequently studied in the context of multidrug resistance phenotypes, tumor cell survival programs, and inflammatory regulation. Altered MVP/LRP expression has also been reported across diverse cancers and neurological and immune-related conditions, supporting its use as a mechanistic node in pathway-focused research.
LRP Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MVP locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MVP. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MVP function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MVP-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.